Targeted Treatments of Non-Small Cell Lung Cancer: Skin Toxicity

This report presents the Taiwanese Dermatological Association's 2016 consensus on defining and managing skin toxicities from EGFR-TKI treatments, providing comprehensive guidelines for clinicians in Taiwan.

The researchers reviewed cepharanthine, a long-used bisbenzylisoquinoline alkaloid, for its antiviral properties, including significant inhibition of SARS-CoV-2. They discussed cepharanthine's other pharmacological actions, highlighted plasma membrane fluidity as a key antiviral mechanism, and examined its safety, bioavailability, and potential for new clinical applications.

This review describes the approved use and adverse effects of gefitinib in patients with advanced non-small cell lung cancer, without presenting new clinical findings.

This review summarizes recent findings on the role of mesenchymal stem cell-derived exosomal microRNAs in skin regeneration and rejuvenation, discussing their potential for treating skin damage and aging, and exploring bioengineering methods to enhance therapeutic effects.

Chemotherapy can cause skin side effects that affect patients' lives, but they can be managed to avoid interrupting cancer treatment.